Clinical Trial

A Trial of HRS-6768 in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is being conducted to evaluate the pharmacokinetics, radiation dosimetry, safety and preliminary efficacy of HRS-6768. To explore the reasonable dosage of HRS-6768 in the treatment of patients with advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-07; most recent amendment 2025-11-26.
Status change: Not Yet Recruiting → Recruiting 2025-05-12
Trial Details
NCT Number NCT06925581
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 84 participants
Start Date 2025-04-24
Primary Completion 2026-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-12-03